Dr Frank Armstrong was appointed a Partner of tranScrip and a member of its Board in September 2015. He brings extensive experience of growing organisations across all aspects of the current collaborative pharma environment.
Frank has been non-executive chairman of NASDAQ since June 2013. He has also previously held Chief Executive roles with five biotechnology companies (public and private) one of which was Fulcrum Pharma, an AIM-listed Professional Services Company that was sold to Private Equity Investors in 2009 and also was a member of the Board at AIM listed Summit plc (LSE: SUMM).
In the past Frank led Medical Science and Innovation (MSI) at Merck Serono and previously was Head of Worldwide Product Development at Bayer, Senior Vice President of Medical Research and Communications Group at Zeneca and Non-Executive Director of Mereo Biopharma. He is also currently the Chairman of Faron Pharmaceuticals (AIM) and Caldan Therapeutics. He is a Member of the Scientific Advisory Board of Healthcare Royalty Partners and a Member of the Court of the University of Edinburgh and is also a Fellow of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine.